Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PSORIASIS-TREAT

Financiado

Cerrado

Directed Evolution of Soluble IL 17A Receptor for Psoriasis Therapeutics

Protein therapeutics has increased dramatically over the last two decades and currently includes more than 130 therapeutic proteins in almost all fields of medicine. However, many proteins are not suitable for therapeutic applicat... ver más

30/06/2015

BGU

168K€

Presupuesto del proyecto: 168K€

Líder del proyecto

BENGURION UNIVERSITY OF THE NEGEV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-06-30 No tenemos la información de la convocatoria

0% 89% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

BGU

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PSORIASIS IL17 Investigating the role of dysregulated Interleukin 17 signal... 208K€ Cerrado

TiilT Preclinical development of a 3rd-generation interleukin-2 ta... 6M€ Cerrado

SAF2013-43833-R ESTUDIO DE LAS CASCADAS DE SEÑALIZACION DE LA CITOQUINA PRO-... 145K€ Cerrado

Notid Novel Target for Treatment of Chronic Inflammatory Diseases 3M€ Cerrado

PDC2022-133701-I00 INFLAMACION TERAPIAS VIRALES 150K€ Cerrado

CPP2021-008475 Valorización de una terapia antígeno-específica para el trat... 639K€ Cerrado

Líder del proyecto

BENGURION UNIVERSITY OF THE NEGEV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 168K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Protein therapeutics has increased dramatically over the last two decades and currently includes more than 130 therapeutic proteins in almost all fields of medicine. However, many proteins are not suitable for therapeutic application due to the lack of sufficient in vivo stability and biological efficacy. Thus, engineering of existing proteins for improved affinity and stability will significantly increase their potential for therapeutic applications. In recent years, the cytokine interleukin 17A (IL-17A) was identified as an important pro-inflammatory protein that plays an essential role in the progression of several autoimmune diseases including psoriasis, rheumatoid arthritis and inflammatory bowel disease. Thus, IL-17A is a promising drug target, and blocking its interactions with the endogenous IL-17RA receptor may constitute an important strategy for the treatment of common autoimmune diseases. We have recently applied protein engineering to generate decoy IL-17RA mutants with improved binding affinity and stability relative to the native soluble receptor. These variants showed promising results in inhibiting psoriasis plaque formation in a human psoriasis mouse model. Here, I propose to further develop the engineered IL-17RA for future pre-clinical and clinical development and pave the way for its commercialization. I propose to perform final lead optimization of the engineered IL-17RA variants by reducing the number of mutations while maintaining the improved characteristics of the engineered receptor. In parallel, I intend to perform detailed intellectual property (IP) and market analysis for identifying the ideal partner to promote the commercialization of the engineered IL-17RA. Further development of engineered IL-17RA and its commercialization will increase our chances for obtaining a highly efficient and a more affordable therapeutic approach for psoriasis and potentially for other common autoimmune diseases.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores